GT Medical Technologies offers GammaTile Therapy, a surgically targeted radiation treatment for patients with operable brain tumors, which is placed at the time of tumor resection. This technology minimizes radiation exposure to healthy tissue, reduces side effects, and ensures 100% treatment compliance, ultimately delaying tumor recurrence and potentially extending patient survival.
Funding
$110.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EHFounders
Product
Problem
Patients with operable brain tumors face the challenge of tumor recurrence after surgical resection. Traditional radiation therapy can damage healthy brain tissue, leading to side effects and impacting quality of life. Ensuring consistent and complete radiation treatment delivery can also be difficult.
Solution
GT Medical Technologies provides GammaTile Therapy, a Surgically Targeted Radiation Therapy (STaRT) for operable brain tumors. This technology involves implanting small, seed-containing collagen tiles directly at the tumor site during resection. By delivering a targeted dose of radiation from within the tumor bed, GammaTile minimizes radiation exposure to surrounding healthy tissue, reducing side effects such as hair loss. The implanted tiles ensure 100% treatment compliance, potentially delaying tumor recurrence and extending patient survival.
Target Audience
The primary audience includes neurosurgeons and radiation oncologists treating patients with newly diagnosed or recurrent operable brain tumors, as well as the patients themselves.
Features
- Surgically targeted radiation delivery directly to the tumor bed
- Collagen tiles containing Cesium-131 radioactive seeds
- Precise placement during tumor resection to target residual tumor cells
- Minimized radiation exposure to surrounding healthy brain tissue
- Reduced side effects compared to traditional external beam radiation
- 100% treatment compliance, eliminating the need for patient adherence to a radiation schedule